Organization
Sorbonne University, Department of Rheumatology, Paris, France
1 abstract
Abstract
A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES (RA-BE-REAL) – STUDY DESIGN AND BASELINE CHARACTERISTICSOrg: University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, Charité Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, University of Florence, Division of Rheumatology, Florence, Italy, CHU de Reims, Traumatologie-Orthopédie, Reims, France, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America,